The division will become its own company, though details on the new entity were not disclosed.
Complaint alleges Willowood infringed patent regarding azoxystrobin.
Sector on track to double market share in the next five years.
Classification as probable carcinogen goes against scientific consensus, industry experts and scientists say.
"Various possibilities" are being examined regarding executing the business combination between the company and the China business.